On June 1, 2016, the U.S. Food and Drug Administration (FDA) granted approval to NETSPOT form Advanced Accelerator Applications (AAA), the first kit for the preparation of Gallium-68 dotatate positron emission tomography (68Ga-dotatate PET) imaging. Gallium-68 dotatate is a positron-emitting analogue of somatostatin, and the radioactive probe helps locate tumors in patients with somatostatin receptor-positive neuroendocrine tumors.

ā€œUse of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,ā€ said Libero Marzella, director of the FDA Division of Medical Imaging Products.

Three studies have established the safety and efficacy of Netspot by comparing 68GA-dotatate PET imaging to standard imaging options as well as clinical and histopathological data in patients with neuroendocrine tumors.

External links to this news: (your browser will open a new window)

FDA Announcement

AAA Press Release